{"id":"JGAD000674","research":"hum0252","url":"https://humandbs.dbcls.jp/dataset/JGAD000674","datePublished":"2023-12-06","dateModified":"2025-12-09","values":[{"key":"access-criteria","label":{"ja":"アクセス制限","en":"Access criteria"},"type":"vocabulary","terms":[{"code":"controlled-access-type-1","label":{"ja":"制限公開（Type I）","en":"Controlled-access (Type I)"}}]},{"key":"type-of-data","label":{"ja":"データの種類","en":"Type of data"},"type":"text","text":{"ja":"NGS（Target Capture、WGS、scRNA-seq、scATAC-seq、ChIP-seq）","en":"NGS (Target Capture, WGS, scRNA-seq, scATAC-seq, ChIP-seq)"}}],"experiments":[{"label":"Targeted DNA sequencing","values":[{"key":"materials-and-participants","label":{"ja":"材料と対象者","en":"Materials and participants"},"type":"text","text":{"ja":"ATL（ICD10：C915）：4＋6症例（計30＋23検体）\n（正常細胞：4＋11検体、バレメトスタット投薬前の腫瘍細胞：4＋6検体、バレメトスタット投薬後の腫瘍細胞：22＋6検体）","en":"ATL (ICD10: C915): 4 + 6 cases (total 30 + 23 samples)\nnon-tumor cells: 4 + 11 samples\ntumor cells: before valemetostat treatment: 4 + 6 samples, after valemetostat treatment: 22 + 6 samples"}},{"key":"disease","label":{"ja":"疾患","en":"Disease"},"type":"disease","diseases":[{"terms":[{"code":"C915","label":{"ja":"成人T細胞リンパ腫／白血病［HTLV-1関連］","en":"Adult T-cell lymphoma/leukaemia [HTLV-1-associated]"}}],"name":{"ja":"ATL","en":"ATL"}}]},{"key":"health-status","label":{"ja":"健康状態","en":"Health status"},"type":"vocabulary","terms":[{"code":"affected","label":{"ja":"罹患","en":"Affected"}}]},{"key":"subject-count","label":{"ja":"対象者数","en":"Subject count"},"type":"number","numbers":[{"value":10,"unit":null,"high":null}]},{"key":"subject-count-type","label":{"ja":"対象者数の数え方","en":"Counted as"},"type":"vocabulary","terms":[{"code":"individual","label":{"ja":"人数","en":"Individual"}}]},{"key":"sample-description","label":{"ja":"試料説明","en":"Sample description"},"type":"text","text":{"ja":"ATL患者及びHTLV-1感染者末梢血の感染細胞分画及び非感染細胞分画ならびに正常細胞および腫瘍細胞から抽出したDNA（CD4+ T細胞、PBMC）","en":"DNAs extracted from infected cells, uninfected cells, non-tumor and tumor cells of ATL and HTLV-1 carriers"}},{"key":"tissue","label":{"ja":"組織","en":"Tissue"},"type":"vocabulary","terms":[{"code":"peripheral-blood","label":{"ja":"末梢血","en":"Peripheral blood"}}]},{"key":"is-tumor","label":{"ja":"腫瘍 / 非腫瘍","en":"Tumor / normal"},"type":"vocabulary","terms":[{"code":"mixed","label":{"ja":"混在","en":"Mixed"}}]},{"key":"sample-provider","label":{"ja":"試料の入手元","en":"Sample provider"},"type":"text","text":{"ja":null,"en":null}},{"key":"experimental-method","label":{"ja":"実験方法","en":"Experimental method"},"type":"vocabulary","terms":[{"code":"targeted-dna-sequencing","label":{"en":"Targeted DNA sequencing"}}]},{"key":"targets","label":{"ja":"測定対象","en":"Target"},"type":"text","text":{"ja":"ATLリスク50遺伝子を含む280遺伝子","en":"280 genes including 50 candidate genes for ATL"}},{"key":"reagents","label":{"ja":"試薬キット","en":"Reagent kit"},"type":"vocabulary","terms":[{"code":"sureselect-target-enrichment-system","label":{"en":"SureSelect Target Enrichment System"}}]},{"key":"fragmentation","label":{"ja":"断片化","en":"Fragmentation"},"type":"text","text":{"ja":"超音波断片化（Covaris）","en":"Ultrasonic fragmentation (Covaris)"}},{"key":"platform","label":{"ja":"プラットフォーム","en":"Platform"},"type":"vocabulary","terms":[{"code":"illumina-hiseq-2500","label":{"en":"Illumina HiSeq 2500"}},{"code":"illumina-hiseq-3000","label":{"en":"Illumina HiSeq 3000"}},{"code":"illumina-novaseq-6000","label":{"en":"Illumina NovaSeq 6000"}}]},{"key":"read-type","label":{"ja":"リードタイプ","en":"Read type"},"type":"vocabulary","terms":[{"code":"paired-end","label":{"ja":"ペアエンド","en":"Paired-end"}}]},{"key":"read-length","label":{"ja":"リード長","en":"Read length"},"type":"number","numbers":[{"value":200,"unit":"bp","high":null,"prefix":{"ja":"JGAD000412、JGAD000674: ","en":"JGAD000412, JGAD000674: "}},{"value":100,"unit":"bp","high":null,"prefix":{"ja":"JGAD000674(追加): ","en":"JGAD000674 (additional): "}}]},{"key":"policies","label":{"ja":"利用ポリシー","en":"Data use policy"},"type":"vocabulary","terms":[{"code":"nbdc-data-sharing-policy-jgap000001","label":{"ja":"NBDC データ共有ポリシー (JGAP000001)","en":"NBDC data sharing policy (JGAP000001)"}}]}]},{"label":"scRNA-seq","values":[{"key":"materials-and-participants","label":{"ja":"材料と対象者","en":"Materials and participants"},"type":"text","text":{"ja":"ATL（ICD10：C915）：3＋3症例（計10＋11検体）\n（末梢血リンパ球 バレメトスタット投薬前：3＋7検体、バレメトスタット投薬後：7＋4検体）","en":"ATL (ICD10: C915): 3 + 3 cases (total 10 + 11 samples)\nperipheral blood lymphocytes: before valemetostat treatment: 3 + 7 samples, after valemetostat treatment: 7 + 4 samples"}},{"key":"disease","label":{"ja":"疾患","en":"Disease"},"type":"disease","diseases":[{"terms":[{"code":"C915","label":{"ja":"成人T細胞リンパ腫／白血病［HTLV-1関連］","en":"Adult T-cell lymphoma/leukaemia [HTLV-1-associated]"}}],"name":{"ja":"ATL","en":"ATL"}}]},{"key":"health-status","label":{"ja":"健康状態","en":"Health status"},"type":"vocabulary","terms":[{"code":"affected","label":{"ja":"罹患","en":"Affected"}}]},{"key":"subject-count","label":{"ja":"対象者数","en":"Subject count"},"type":"number","numbers":[{"value":6,"unit":null,"high":null}]},{"key":"subject-count-type","label":{"ja":"対象者数の数え方","en":"Counted as"},"type":"vocabulary","terms":[{"code":"individual","label":{"ja":"人数","en":"Individual"}}]},{"key":"sample-description","label":{"ja":"試料説明","en":"Sample description"},"type":"text","text":{"ja":"ATL患者末梢血の感染細胞分画、非感染細胞分画のCD4+T細胞（シングルセル）および末梢血リンパ球から抽出したRNA","en":"RNAs extracted from single CD4+ T cells with/without infection of ATL or peripheral blood lymphocytes of ATL cases before and after valemetostat treatment"}},{"key":"tissue","label":{"ja":"組織","en":"Tissue"},"type":"vocabulary","terms":[{"code":"peripheral-blood","label":{"ja":"末梢血","en":"Peripheral blood"}}]},{"key":"is-tumor","label":{"ja":"腫瘍 / 非腫瘍","en":"Tumor / normal"},"type":"vocabulary","terms":[{"code":"tumor","label":{"ja":"腫瘍","en":"Tumor"}}]},{"key":"sample-provider","label":{"ja":"試料の入手元","en":"Sample provider"},"type":"text","text":{"ja":null,"en":null}},{"key":"experimental-method","label":{"ja":"実験方法","en":"Experimental method"},"type":"vocabulary","terms":[{"code":"scrna-seq","label":{"en":"scRNA-seq"}}]},{"key":"targets","label":{"ja":"測定対象","en":"Target"},"type":"text","text":{"ja":null,"en":null}},{"key":"reagents","label":{"ja":"試薬キット","en":"Reagent kit"},"type":"vocabulary","terms":[{"code":"chromium-single-cell-3-v2","label":{"en":"Chromium Single Cell 3' v2"}},{"code":"chromium-single-cell-5","label":{"en":"Chromium Single Cell 5'"}}]},{"key":"fragmentation","label":{"ja":"断片化","en":"Fragmentation"},"type":"text","text":{"ja":"上記キットに準拠（酵素反応）","en":"included in the above library construction kit (enzymatic fragmentation)"}},{"key":"platform","label":{"ja":"プラットフォーム","en":"Platform"},"type":"vocabulary","terms":[{"code":"illumina-hiseq-2500","label":{"en":"Illumina HiSeq 2500"}},{"code":"illumina-hiseq-3000","label":{"en":"Illumina HiSeq 3000"}},{"code":"illumina-novaseq-6000","label":{"en":"Illumina NovaSeq 6000"}}]},{"key":"read-type","label":{"ja":"リードタイプ","en":"Read type"},"type":"vocabulary","terms":[{"code":"mixed","label":{"ja":"混在","en":"Mixed"}}]},{"key":"read-length","label":{"ja":"リード長","en":"Read length"},"type":"number","numbers":[{"value":124,"unit":"bp","high":null,"prefix":{"ja":"JGAD000412、JGAD000674: ","en":"JGAD000412, JGAD000674: "}},{"value":91,"unit":"bp","high":98,"prefix":{"ja":"JGAD000674(追加): ","en":"JGAD000674 (additional): "}}]},{"key":"policies","label":{"ja":"利用ポリシー","en":"Data use policy"},"type":"vocabulary","terms":[{"code":"nbdc-data-sharing-policy-jgap000001","label":{"ja":"NBDC データ共有ポリシー (JGAP000001)","en":"NBDC data sharing policy (JGAP000001)"}}]}]},{"label":"WGS","values":[{"key":"materials-and-participants","label":{"ja":"材料と対象者","en":"Materials and participants"},"type":"text","text":{"ja":"ATL（ICD10：C915）：3症例（計9検体）\n（正常細胞：3検体、バレメトスタット投薬前の腫瘍細胞：3検体、バレメトスタット投薬後の腫瘍細胞：3検体）","en":"ATL (ICD10: C915): 3 cases (total 9 samples)\nnon-tumor cells: 3 samples\ntumor cells: before valemetostat treatment: 3 samples, after valemetostat treatment: 3 samples"}},{"key":"disease","label":{"ja":"疾患","en":"Disease"},"type":"disease","diseases":[{"terms":[{"code":"C915","label":{"ja":"成人T細胞リンパ腫／白血病［HTLV-1関連］","en":"Adult T-cell lymphoma/leukaemia [HTLV-1-associated]"}}],"name":{"ja":"ATL","en":"ATL"}}]},{"key":"health-status","label":{"ja":"健康状態","en":"Health status"},"type":"vocabulary","terms":[{"code":"affected","label":{"ja":"罹患","en":"Affected"}}]},{"key":"subject-count","label":{"ja":"対象者数","en":"Subject count"},"type":"number","numbers":[{"value":3,"unit":null,"high":null}]},{"key":"subject-count-type","label":{"ja":"対象者数の数え方","en":"Counted as"},"type":"vocabulary","terms":[{"code":"individual","label":{"ja":"人数","en":"Individual"}}]},{"key":"sample-description","label":{"ja":"試料説明","en":"Sample description"},"type":"text","text":{"ja":"ATL患者の正常細胞および腫瘍細胞から抽出したDNA","en":"DNAs extracted from normal cells and tumor cells"}},{"key":"is-tumor","label":{"ja":"腫瘍 / 非腫瘍","en":"Tumor / normal"},"type":"vocabulary","terms":[{"code":"mixed","label":{"ja":"混在","en":"Mixed"}}]},{"key":"sample-provider","label":{"ja":"試料の入手元","en":"Sample provider"},"type":"text","text":{"ja":null,"en":null}},{"key":"experimental-method","label":{"ja":"実験方法","en":"Experimental method"},"type":"vocabulary","terms":[{"code":"wgs","label":{"en":"WGS"}}]},{"key":"targets","label":{"ja":"測定対象","en":"Target"},"type":"text","text":{"ja":null,"en":null}},{"key":"reagents","label":{"ja":"試薬キット","en":"Reagent kit"},"type":"vocabulary","terms":[{"code":"mgieasy-pcr-free-dna-library-prep-set","label":{"en":"MGIEasy PCR-Free DNA Library Prep Set"}}]},{"key":"fragmentation","label":{"ja":"断片化","en":"Fragmentation"},"type":"text","text":{"ja":"超音波断片化（Covaris）","en":"Ultrasonic fragmentation (Covaris)"}},{"key":"platform","label":{"ja":"プラットフォーム","en":"Platform"},"type":"vocabulary","terms":[{"code":"mgi-dnbseq-g400","label":{"en":"MGI DNBSEQ-G400"}}]},{"key":"read-type","label":{"ja":"リードタイプ","en":"Read type"},"type":"vocabulary","terms":[{"code":"paired-end","label":{"ja":"ペアエンド","en":"Paired-end"}}]},{"key":"read-length","label":{"ja":"リード長","en":"Read length"},"type":"number","numbers":[{"value":300,"unit":"bp","high":null}]},{"key":"policies","label":{"ja":"利用ポリシー","en":"Data use policy"},"type":"vocabulary","terms":[{"code":"nbdc-data-sharing-policy-jgap000001","label":{"ja":"NBDC データ共有ポリシー (JGAP000001)","en":"NBDC data sharing policy (JGAP000001)"}}]}]},{"label":"scATAC-seq","values":[{"key":"materials-and-participants","label":{"ja":"材料と対象者","en":"Materials and participants"},"type":"text","text":{"ja":"ATL（ICD10：C915）：3＋3症例（計10＋11検体）\n（末梢血リンパ球 バレメトスタット投薬前：3＋7検体、バレメトスタット投薬後：7＋4検体）","en":"ATL (ICD10: C915): 3 + 3 cases (total 10 + 11 samples)\nperipheral blood lymphocytes: before valemetostat treatment: 3 + 7 samples, after valemetostat treatment: 7 + 4 samples"}},{"key":"disease","label":{"ja":"疾患","en":"Disease"},"type":"disease","diseases":[{"terms":[{"code":"C915","label":{"ja":"成人T細胞リンパ腫／白血病［HTLV-1関連］","en":"Adult T-cell lymphoma/leukaemia [HTLV-1-associated]"}}],"name":{"ja":"ATL","en":"ATL"}}]},{"key":"health-status","label":{"ja":"健康状態","en":"Health status"},"type":"vocabulary","terms":[{"code":"affected","label":{"ja":"罹患","en":"Affected"}}]},{"key":"subject-count","label":{"ja":"対象者数","en":"Subject count"},"type":"number","numbers":[{"value":21,"unit":null,"high":null}]},{"key":"subject-count-type","label":{"ja":"対象者数の数え方","en":"Counted as"},"type":"vocabulary","terms":[{"code":"sample","label":{"ja":"検体数","en":"Sample"}}]},{"key":"sample-description","label":{"ja":"試料説明","en":"Sample description"},"type":"text","text":{"ja":"ATL患者のリンパ球から抽出したDNA","en":"DNAs extracted from peripheral blood lymphocytes of ATL cases before and after valemetostat treatment"}},{"key":"tissue","label":{"ja":"組織","en":"Tissue"},"type":"vocabulary","terms":[{"code":"peripheral-blood","label":{"ja":"末梢血","en":"Peripheral blood"}},{"code":"lymphocyte","label":{"ja":"リンパ球","en":"Lymphocyte"}}]},{"key":"sample-provider","label":{"ja":"試料の入手元","en":"Sample provider"},"type":"text","text":{"ja":null,"en":null}},{"key":"experimental-method","label":{"ja":"実験方法","en":"Experimental method"},"type":"vocabulary","terms":[{"code":"scatac-seq","label":{"en":"scATAC-seq"}}]},{"key":"targets","label":{"ja":"測定対象","en":"Target"},"type":"text","text":{"ja":null,"en":null}},{"key":"reagents","label":{"ja":"試薬キット","en":"Reagent kit"},"type":"vocabulary","terms":[{"code":"chromium-next-gem-single-cell-atac-v1-1","label":{"en":"Chromium Next GEM Single Cell ATAC v1.1"}}]},{"key":"fragmentation","label":{"ja":"断片化","en":"Fragmentation"},"type":"text","text":{"ja":"酵素反応","en":"enzymatic fragmentation"}},{"key":"platform","label":{"ja":"プラットフォーム","en":"Platform"},"type":"vocabulary","terms":[{"code":"illumina-novaseq-6000","label":{"en":"Illumina NovaSeq 6000"}}]},{"key":"read-type","label":{"ja":"リードタイプ","en":"Read type"},"type":"vocabulary","terms":[{"code":"paired-end","label":{"ja":"ペアエンド","en":"Paired-end"}}]},{"key":"read-length","label":{"ja":"リード長","en":"Read length"},"type":"number","numbers":[{"value":100,"unit":"bp","high":null},{"value":49,"unit":"bp","high":null,"prefix":{"ja":"JGAD000674(追加): ","en":"JGAD000674 (additional): "},"suffix":{"ja":" (50×)","en":" (50×)"}}]},{"key":"policies","label":{"ja":"利用ポリシー","en":"Data use policy"},"type":"vocabulary","terms":[{"code":"nbdc-data-sharing-policy-jgap000001","label":{"ja":"NBDC データ共有ポリシー (JGAP000001)","en":"NBDC data sharing policy (JGAP000001)"}}]}]},{"label":"ChIP-seq","values":[{"key":"materials-and-participants","label":{"ja":"材料と対象者","en":"Materials and participants"},"type":"text","text":{"ja":"ATL（ICD10：C915）：1＋2症例\n健常者：1名（セルライン）","en":"ATL (ICD10: C915): 1 + 2 case\nCD4+ T cells from 1 cell line"}},{"key":"disease","label":{"ja":"疾患","en":"Disease"},"type":"disease","diseases":[{"terms":[{"code":"C915","label":{"ja":"成人T細胞リンパ腫／白血病［HTLV-1関連］","en":"Adult T-cell lymphoma/leukaemia [HTLV-1-associated]"}}],"name":{"ja":"ATL","en":"ATL"}}]},{"key":"health-status","label":{"ja":"健康状態","en":"Health status"},"type":"vocabulary","terms":[{"code":"mixed","label":{"ja":"混在","en":"Mixed"}}]},{"key":"subject-count","label":{"ja":"対象者数","en":"Subject count"},"type":"number","numbers":[{"value":4,"unit":null,"high":null}]},{"key":"subject-count-type","label":{"ja":"対象者数の数え方","en":"Counted as"},"type":"vocabulary","terms":[{"code":"individual","label":{"ja":"人数","en":"Individual"}}]},{"key":"sample-description","label":{"ja":"試料説明","en":"Sample description"},"type":"text","text":{"ja":"ATL患者腫瘍細胞および健常者のCD4+T細胞より抽出したDNAについて免疫沈降（H3K27me3、H3K27ac）を実施\n・ATL患者腫瘍細胞\nバレメトスタット投薬前：コントロール 1＋2検体、免疫沈降 2＋2検体\nバレメトスタット投薬後：免疫沈降 2＋4検体\n・健常者：コントロール 1検体、免疫沈降 2検体","en":"DNAs extracted from CD4+ T cells and tumor cells and immunoprecipitated with anti-histone antibodies (H3K27me3, H3K27ac)\nATL tumor cells before valemetostat treatment: control 1 + 2 sample, ChIP 2 + 2 samples\nATL tumor cells after valemetostat treatment: ChIP 2 + 4 samples\nCD4+ T cells: control 1 sample, ChIP 2 samples"}},{"key":"tissue","label":{"ja":"組織","en":"Tissue"},"type":"vocabulary","terms":[{"code":"cd4-t-cell","label":{"ja":"CD4 陽性 T 細胞","en":"CD4+ T cell"}}]},{"key":"is-tumor","label":{"ja":"腫瘍 / 非腫瘍","en":"Tumor / normal"},"type":"vocabulary","terms":[{"code":"mixed","label":{"ja":"混在","en":"Mixed"}}]},{"key":"sample-provider","label":{"ja":"試料の入手元","en":"Sample provider"},"type":"text","text":{"ja":"ヒト末梢血CD4+T細胞（Lonza Catalog #: 2W-200）","en":"Human Peripheral Blood CD4+ T cells (Lonza Catalog #: 2W-200)"}},{"key":"experimental-method","label":{"ja":"実験方法","en":"Experimental method"},"type":"vocabulary","terms":[{"code":"chip-seq","label":{"en":"ChIP-seq"}}]},{"key":"targets","label":{"ja":"測定対象","en":"Target"},"type":"text","text":{"ja":null,"en":null}},{"key":"fragmentation","label":{"ja":"断片化","en":"Fragmentation"},"type":"text","text":{"ja":"超音波断片化（Covaris）","en":"Ultrasonic fragmentation (Covaris)"}},{"key":"platform","label":{"ja":"プラットフォーム","en":"Platform"},"type":"vocabulary","terms":[{"code":"illumina-nextseq-500","label":{"en":"Illumina NextSeq 500"}}]},{"key":"read-type","label":{"ja":"リードタイプ","en":"Read type"},"type":"vocabulary","terms":[{"code":"single-end","label":{"ja":"シングルエンド","en":"Single-end"}}]},{"key":"read-length","label":{"ja":"リード長","en":"Read length"},"type":"number","numbers":[{"value":75,"unit":"bp","high":null}]},{"key":"policies","label":{"ja":"利用ポリシー","en":"Data use policy"},"type":"vocabulary","terms":[{"code":"nbdc-data-sharing-policy-jgap000001","label":{"ja":"NBDC データ共有ポリシー (JGAP000001)","en":"NBDC data sharing policy (JGAP000001)"}}]}]}],"dataVolume":4745298227406,"fileFormats":[{"code":"fastq","label":{"en":"FASTQ"}}]}